Sinopharm Group Co Ltd Class H (HK:1099)
:1099
Want to see HK:1099 full AI Analyst Report?
Total Valuation
Sinopharm Group Co has a market cap or net worth of HK$58.61B. The enterprise value is HK$98.15B.
Market CapHK$58.61B
Enterprise ValueHK$98.15B
Share Statistics
Sinopharm Group Co has 1,341,810,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,341,810,800
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Sinopharm Group Co’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 5.70%.
Return on Equity (ROE)0.08
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)5.70%
Return on Capital Employed (ROCE)0.11
Revenue Per Employee5.18M
Profits Per Employee136.76K
Employee Count108,217
Asset Turnover1.43
Inventory Turnover8.21
Valuation Ratios
The current PE Ratio of Sinopharm Group Co is 7.8. Sinopharm Group Co’s PEG ratio is -8.83.
PE Ratio7.8
PS Ratio0.10
PB Ratio0.65
Price to Fair Value0.65
Price to FCF4.35
Price to Operating Cash Flow4.24
PEG Ratio-8.83
Income Statement
In the last 12 months, Sinopharm Group Co had revenue of 560.28B and earned 6.97B in profits. Earnings per share was 2.24.
Revenue560.28B
Gross Profit40.15B
Operating Income16.24B
Pretax Income14.42B
Net Income6.97B
EBITDA20.41B
Earnings Per Share (EPS)2.24
Cash Flow
In the last 12 months, operating cash flow was 12.05B and capital expenditures -1.55B, giving a free cash flow of 10.50B billion.
Operating Cash Flow12.05B
Free Cash Flow10.50B
Free Cash Flow per Share7.83
Dividends & Yields
Sinopharm Group Co pays an annual dividend of HK$0.739, resulting in a dividend yield of 3.75%
Dividend Per ShareHK$0.739
Dividend Yield3.75%
Payout Ratio29.44%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.72
52-Week Price Change6.50%
50-Day Moving Average20.91
200-Day Moving Average19.81
Relative Strength Index (RSI)44.83
Average Volume (3m)4.67M
Important Dates
Sinopharm Group Co upcoming earnings date is Aug 31, 2026, TBA (Not Confirmed).
Last Earnings DateApr 27, 2026
Next Earnings DateAug 31, 2026
Ex-Dividend Date―
Financial Position
Sinopharm Group Co as a current ratio of 1.41, with Debt / Equity ratio of 129.33%
Current Ratio1.41
Quick Ratio1.15
Debt to Market Cap1.23
Net Debt to EBITDA2.30
Interest Coverage Ratio6.68
Taxes
In the past 12 months, Sinopharm Group Co has paid 3.86B in taxes.
Income Tax3.86B
Effective Tax Rate0.27
Enterprise Valuation
Sinopharm Group Co EV to EBITDA ratio is 4.97, with an EV/FCF ratio of 8.11.
EV to Sales0.18
EV to EBITDA4.97
EV to Free Cash Flow8.11
EV to Operating Cash Flow7.18
Balance Sheet
Sinopharm Group Co has HK$61.59B in cash and marketable securities with HK$108.63B in debt, giving a net cash position of -HK$47.04B billion.
Cash & Marketable SecuritiesHK$61.59B
Total DebtHK$108.63B
Net Cash-HK$47.04B
Net Cash Per Share-HK$35.06
Tangible Book Value Per ShareHK$39.76
Margins
Gross margin is 7.28%, with operating margin of 2.90%, and net profit margin of 1.24%.
Gross Margin7.28%
Operating Margin2.90%
Pretax Margin2.57%
Net Profit Margin1.24%
EBITDA Margin3.64%
EBIT Margin2.90%
Analyst Forecast
The average price target for Sinopharm Group Co is HK$23.32, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetHK$23.32
Price Target Upside15.00% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast-1.57%
EPS Growth Forecast1.55%